© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#lopinavir

Switching to Symtuza Is Safe and Effective Regardless of Previous HIV Regimen

Janssen’s single-tablet antiretroviral regimen was approved on July 17.

PrEP Protects Breastfeeding Infants From HIV for Up to a Year

HIV-positive women who breastfeed can protect their infants from infection for a year after birth by giving them a liquid form of PrEP.

HIV Essentially Doubles Aging’s Effect on Heart Attack Risk

Every decade spent living with HIV is equivalent to an additional 10 years of ordinary aging’s contribution to heart attack risk.

Of Meds, ’Boosters’ Most Likely to Clash With Recreational Drugs

Medications used to boost the levels of other HIV antiretrovirals are the most likely out of all ARVs to have dangerous interactions with...

Several HIV Meds Steadily Raise Kidney Disease Risk Over Time

People with HIV who take Viread, Norvir, Reyataz or Norvir-boosted Kaletra are at increasing risk of kidney disease over time.

AbbVie Licenses 2 Pediatric HIV Meds for Developing World

The agreement will allow for the generic production of HIV meds lopinavir and ritonavir.

Mother-to-Child HIV Transmission Is Best Prevented With 3 Drugs

Taking a triple-antiretroviral regimen is best for preventing mother-to-child transmission during pregnancy, rather than taking one drug durin...

FDA Approves Gilead’s Vitekta (Elvitegravir) to Treat HIV

The FDA has approved Gilead Sciences’ integrase strand transfer inhibitor Vitekta (elvitegravir) for treatment-experienced HIV-positive...

Ugandans Starting HIV Treatment Early Fare Very Well

Ugandans with HIV who begin treatment with higher CD4 counts can do quite well on therapy

Kaletra and Epivir Dual Therapy Works as Well as Triple Combo

Treating HIV with a dual regimen of Kaletra and Epivir is as effective as a standard triple regimen of Kaletra plus two NRTIs.

Lower Dose of Kaletra Works Well for Kids With HIV

Cutting the standard dose of Kaletra by 30 percent does not change its efficacy at suppressing HIV and it improves abnormal lipid levels among...

FDA Updates Atripla Label

The U.S. Food and Drug Administration has made changes to the label for the single-pill HIV antiretroviral combination therapy Atripla.

Protease Inhibitors During First Trimester Raise Risk of Premature Births

Pregnant women’s use of protease inhibitors, but not nukes or non-nukes, in the first trimester increases their risk of premature birth.

FDA to Docs: Best to Avoid Victrelis With Norvir-Boosted HIV Protease Inhibitors

Victrelis (boceprevir), Merck’s hepatitis C virus (HCV) protease inhibitor, should not be combined with the following Norvir (ritonavir)...

Merck Warns of Victrelis and HIV Protease Inhibitor Interactions

The hepatitis C protease inhibitor Victrelis (boceprevir) has some significant drug-drug interactions with common Norvir (ritonavir)?boosted p...

Crushed Kaletra Tablets Not Recommend for Children Living With HIV

Crushing Kaletra (lopinavir/ritonavir) tablets to make the medication easier to take by children should be avoided, according to a new paper p...
Advertisement